It is reported that Optima Neurosciences was acquired in September 2011 by fellow SBIR Awardeee Tucker-Davis. Still under the Optima name, the latter firm continued (until 2017) to receive SBIR funding on a 2009 initiated project. Optima Neuroscience had been a medical device company developing innovative technologies for the diagnosis and treatment of neurological disorders. Drawing on years of research in EEG analysis, Optima focused to creating products to improve the quality of patient care of the more than 10 million patients hospitalized annually due to acute brain injuries including head trauma, TIAs and stroke. Withlimited capability automatically to detect and predict seizures in these patients a high percentage of these patients are misdiagnosed annually. This result in preventable brain damage and loss of neurological function due to ongoing but untreated seizures. In addition, individuals suffering from seizure disorders such as epilepsy are often left searching for better solutions than currently available medical and surgical therapies. Optima's initial product lines feature neurological status monitoring technologies designed to directly address these needs
